Forecasting Pneumonitis Associated with Immune Checkpoint Inhibitors in Lung Cancer: Creation and Assessment of Various Machine Learning Models - Scorecard - MDSpire
Advertisement
Forecasting Pneumonitis Associated with Immune Checkpoint Inhibitors in Lung Cancer: Creation and Assessment of Various Machine Learning Models
Clinical Scorecard: Forecasting Pneumonitis Associated with Immune Checkpoint Inhibitors in Lung Cancer: Creation and Assessment of Various Machine Learning Models
At a Glance
Category
Detail
Condition
Checkpoint Inhibitor Pneumonitis (CIP)
Key Mechanisms
Immune-related adverse events (irAEs) due to nonspecific immune activation.
Target Population
Lung cancer patients receiving immune checkpoint inhibitors.
Care Setting
Multicenter, retrospective clinical study.
Key Highlights
CIP incidence ranges from 3% to 19% in clinical and real-world studies.
CIP can lead to severe respiratory symptoms and is a significant cause of mortality among irAEs.
Predictive models for CIP have shown satisfactory generalizability and predictive capabilities.
Guideline-Based Recommendations
Diagnosis
Diagnosis based on respiratory symptoms and new infiltrates on chest imaging, excluding infections.
Management
Suspend immunotherapy and initiate corticosteroid therapy with empirical anti-infective treatment.
Monitoring & Follow-up
Vigilance in monitoring for symptoms of CIP in lung cancer patients on ICIs.
Risks
CIP accounts for approximately 35% of deaths related to immune-related adverse events.
Patient & Prescribing Data
210 lung cancer patients treated with immune checkpoint inhibitors.
CIP can manifest from asymptomatic to severe acute respiratory distress syndrome.
Clinical Best Practices
Utilize multiple noninvasive risk prediction models for estimating CIP risk.
Incorporate demographic and clinical features in predictive modeling.
